venBio Partners’s Apellis Pharmaceuticals APLS Stock Holding History

venBio Partners’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-411,471	Closed	-$26M	–	10
2021 Q2	$26M	Sell	411,471 -79,000	-16%	-$4.08M	3.07%	6
2021 Q1	$21M	Hold	490,471	–	–	2%	6
2020 Q4	$28.1M	Sell	490,471 -11,113	-2%	-$470K	2.48%	5
2020 Q3	$15.1M	Hold	501,584	–	–	2.3%	6
2020 Q2	$16.4M	Hold	501,584	–	–	13.62%	3
2020 Q1	$13.4M	Sell	501,584 -498,416	-50%	-$17.7M	11.45%	3
2019 Q4	$30.6M	Hold	1,000,000	–	–	13.13%	4
2019 Q3	$24.1M	Hold	1,000,000	–	–	11.43%	4
2019 Q2	$25.3M	Sell	1,000,000 -526,122	-34%	-$10.7M	11.24%	4
2019 Q1	$29.8M	Sell	1,526,122 -263,980	-15%	-$4.15M	24.1%	2
2018 Q4	$23.6M	Buy	+1,790,102	New	+$27.5M	62.01%	1

Other funds holding APLS

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

venBio Partners's APLS Position: Q3 2021 in Review

venBio Partners sold out of Apellis Pharmaceuticals (APLS) in Q3 2021, closing a stake of 411,471 shares — an estimated $26M sold.

venBio Partners first reported a position in APLS in Q4 2018 and held it in 11 quarters. The position peaked at $30.6M in Q4 2019. 180 funds tracked by Wall St. Rank hold APLS as of Q3 2021.

venBio Partners reported no remaining Apellis Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
venBio Partners sold 411,471 Apellis Pharmaceuticals shares in Q3 2021, an estimated $26M.
venBio Partners first reported a position in Apellis Pharmaceuticals in Q4 2018 and held it in 11 quarters.
venBio Partners's Apellis Pharmaceuticals position peaked at $30.6M in Q4 2019.
180 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2021.

Based on venBio Partners's 13F filing for Q3 2021, filed 15 Nov 2021.